Literature DB >> 22965430

Refractory inflammatory bowel disease-could it be an irritable bowel?

Jie Meng1, Anurag Agrawal, Peter J Whorwell.   

Abstract

Patients with IBD who are apparently in remission-as indicated by normal blood tests, endoscopic findings and ultrasonography results-often continue to experience symptoms. Furthermore, despite these negative findings, there is a temptation to increase their anti-inflammatory medication in the hope that this approach would lead to some improvement. However, this strategy often seems to fail and can sometimes lead to adverse events. Consequently, when evidence of continuing inflammatory activity is lacking it might be appropriate to consider the possibility of co-existent IBS in these patients and to treat them for this condition. Dietary manipulation, antispasmodic agents, antidepressants (especially of the tricyclic variety) and even behavioural treatments might result in a worthwhile improvement of symptoms.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22965430     DOI: 10.1038/nrgastro.2012.173

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  51 in total

1.  Remission induction and maintenance effect of probiotics on ulcerative colitis: a meta-analysis.

Authors:  Li-Xuan Sang; Bing Chang; Wen-Liang Zhang; Xiao-Mei Wu; Xiao-Hang Li; Min Jiang
Journal:  World J Gastroenterol       Date:  2010-04-21       Impact factor: 5.742

Review 2.  Probiotics for maintenance of remission in Crohn's disease.

Authors:  V E Rolfe; P J Fortun; C J Hawkey; F Bath-Hextall
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

3.  Overlap between irritable bowel syndrome and inflammatory bowel disease.

Authors:  Robin C Spiller
Journal:  Dig Dis       Date:  2010-03-04       Impact factor: 2.404

4.  Managing symptoms of irritable bowel syndrome in patients with inflammatory bowel disease.

Authors:  Michael Camilleri
Journal:  Gut       Date:  2011-02-02       Impact factor: 23.059

5.  Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors.

Authors:  Magnus Simrén; Jenny Axelsson; Rolf Gillberg; Hasse Abrahamsson; Jan Svedlund; Einar S Björnsson
Journal:  Am J Gastroenterol       Date:  2002-02       Impact factor: 10.864

Review 6.  Faecal calprotectin -- a useful tool in the management of inflammatory bowel disease.

Authors:  Emanuel Burri; Christoph Beglinger
Journal:  Swiss Med Wkly       Date:  2012-04-05       Impact factor: 2.193

7.  Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome.

Authors:  QiQi Zhou; Buyi Zhang; G Nicholas Verne
Journal:  Pain       Date:  2009-11       Impact factor: 6.961

Review 8.  Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis.

Authors:  A C Ford; N J Talley; P S Schoenfeld; E M M Quigley; P Moayyedi
Journal:  Gut       Date:  2008-11-10       Impact factor: 23.059

9.  Intestinal microbiota in functional bowel disorders: a Rome foundation report.

Authors:  Magnus Simrén; Giovanni Barbara; Harry J Flint; Brennan M R Spiegel; Robin C Spiller; Stephen Vanner; Elena F Verdu; Peter J Whorwell; Erwin G Zoetendal
Journal:  Gut       Date:  2012-06-22       Impact factor: 23.059

10.  Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome.

Authors:  I M Carroll; T Ringel-Kulka; J P Siddle; Y Ringel
Journal:  Neurogastroenterol Motil       Date:  2012-02-20       Impact factor: 3.598

View more
  5 in total

1.  Tricyclic antidepressants for management of residual symptoms in inflammatory bowel disease.

Authors:  Heba N Iskandar; Benjamin Cassell; Navya Kanuri; C Prakash Gyawali; Alexandra Gutierrez; Themistocles Dassopoulos; Matthew A Ciorba; Gregory S Sayuk
Journal:  J Clin Gastroenterol       Date:  2014 May-Jun       Impact factor: 3.062

Review 2.  Diagnosis and management of functional symptoms in inflammatory bowel disease in remission.

Authors:  Carlos Teruel; Elena Garrido; Francisco Mesonero
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

Review 3.  Inflammatory bowel diseases: Current problems and future tasks.

Authors:  Giovanni C Actis; Rinaldo Pellicano; Floriano Rosina
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-08-06

Review 4.  The Brain-Gut Axis: Psychological Functioning and Inflammatory Bowel Diseases.

Authors:  Spyros Peppas; Claudia Pansieri; Daniele Piovani; Silvio Danese; Laurent Peyrin-Biroulet; Andreas G Tsantes; Enrico Brunetta; Argirios E Tsantes; Stefanos Bonovas
Journal:  J Clin Med       Date:  2021-01-20       Impact factor: 4.241

Review 5.  Functional gastrointestinal disorders in inflammatory bowel disease: Time for a paradigm shift?

Authors:  Dipesh H Vasant; Alexander C Ford
Journal:  World J Gastroenterol       Date:  2020-07-14       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.